Vertex Pharmaceuticals (VRTX) Should Remain Supported

Vertex Pharmaceuticals Incorporated (VRTX), is a biotechnology company. It engages in developing & commercializing therapies for treating cystic fibrosis (CF).

Vertex Pharmaceuticals Incorporated (VRTX), is a biotechnology company. It engages in developing & commercializing therapies for treating cystic fibrosis (CF). The company has collaborations with CRISPR Therapeutics AG, Moderna Inc, Entrada Therapeutics Inc, Arbor Biotechnologies Inc, Mammoth Biosciences Inc & Verve Therapeutics. It is based in Boston, US, comes under Healthcare sector & trades as “VRTX” ticker at Nasdaq. It is having 111.9 B$ market cap as on 26-Feb,2024.

VRTX trading at weekly highs as the part of impulse sequence within ((3)) of III & expect to remain supported in 3, 7 or 11 swings.

VRTX - Elliott Wave Latest Weekly View: 

In weekly, it placed ((II)) at $176.36 low in October-2021 & favors upside in ((III)) as it broke above ((I)) high. It placed (II) at $233.01 low & II at $282.21 low. Above there, it ended ((1)) of III at $387.42 high & ((2)) at $341.90 low. Within ((1)), it placed (1) at $325.19 high, (2) at $283.60 low, (3) at $354.46 high, (4) at $320.01 low & finally (5) as diagonal at $387.42 high. It corrected in ((2)) as 0.382 Fibonacci retracement of ((1)) sequence.

VRTX - Elliott Wave Latest Daily View: 

Above ((2)) low, it extended higher in (1) of ((3)) of III, which ended at $448.40 high. Later, it corrected lower in (2) as sharp pullback at $410.80 low as 0.382 Fibonacci retracement. Above there, it favors upside in (3) of ((3)), which confirms above (1) high of $448.40. Until then, it still may extend lower as double in (2), if breaks below $410.80 low before it should resume higher in (3). Currently, it favors upside in 1 of (3) & expect impulse sequence to confirm it in (3). We like to buy the pullback in 3, 7 or 11 swings at extreme areas, when reached.

Source: https://elliottwave-forecast.com/stock-market/vertex-pharmaceticals-remain-supported/

Disclaimer: This and other personal blog posts are not reviewed, monitored or endorsed by TalkMarkets. The content is solely the view of the author and TalkMarkets is not responsible for the content of this post in any way. Our curated content which is handpicked by our editorial team may be viewed here.

STOCKS IN THIS BLOG POST

Comments